Supriya Lifescience Ltd has initiated a postal ballot process to seek shareholder approval for the re-appointment of Mr. Balasaheb Sawant as Whole Time Director and Key Managerial Personnel of the Company. The resolution proposes a tenure of three consecutive years, effective from May 26, 2026, to May 25, 2029. The Board of Directors has recommended the appointment based on Mr. Sawant's experience and contributions to the Company.

The remote e-voting period commences on Thursday, July 23, 2026, at 9.00 a.m. IST and concludes on Friday, August 21, 2026, at 5.00 p.m. IST. Shareholders whose names appear on the Register of Members or List of Beneficial Owners as on the cut-off date of Friday, July 17, 2026, are eligible to participate. The Company has engaged National Securities Depository Limited (NSDL) to facilitate the remote e-voting process.

Re-appointment Details

The resolution seeks approval for the re-appointment of Mr. Balasaheb Sawant (DIN: 07743507). The remuneration proposed is not exceeding ₹8,78,080 per month, which includes basic salary, house rent allowance, perquisites, allowances, bonus, and performance incentives. The appointment is subject to the approval of the Central Government if the Company has no profits or inadequate profits in any financial year during the tenure.

Voting Process and Scrutiny

CS Sanam Umbargikar, Partner of M/s. DSM & Associates, Company Secretaries, has been appointed as the Scrutinizer to ensure the e-voting process is conducted fairly. The results of the postal ballot will be declared on or before Saturday, August 22, 2026, at the Registered Office of the Company. The results, along with the Scrutinizer's Report, will be communicated to the National Stock Exchange of India Limited and BSE Limited and displayed on the Company's website.

Mr. Balasaheb Sawant possesses over 29 years of experience in API Production Planning, Material Management, and process enhancement. He has previously held leadership roles at USV Limited, Encure Pharmaceuticals Limited, Arch Pharmalabs Limited, Mylan Laboratories Limited, and Enaltec Labs Private Limited. He does not hold any shares in the Company.

Supriya Lifescience Ltd disclosed that its General Manager, Sales & Marketing, Sreekant Sreedharan, has been granted judicial custody until July 17, 2026. The Special Investigation and Intelligence branch of the Customs Department initiated an investigation against the officer on July 3, 2026, under the Narcotic Drugs and Psychotropic Substances (NDPS) Act, 1985. The proceedings relate to an alleged procedural lapse for a single export transaction of an identified product.

The company stated that based on currently available information, the legal proceedings are not expected to have a material impact on its operations, financial position, or governance. Supriya Lifescience is evaluating the implications of the case and obtaining appropriate legal advice. The matter is currently before the competent court, and the company intends to take appropriate action after examining all applicable legal provisions.

The disclosure was made to the stock exchanges in accordance with Regulation 30 read with Para B of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and a SEBI circular dated July 13, 2023.

Details of the Proceedings

The following table outlines the key details of the case as provided in the regulatory filing:

Supriya Lifescience affirmed its commitment to maintaining high standards of corporate governance and regulatory compliance. The company is closely monitoring developments and will disclose any further material information to the exchanges in accordance with applicable laws.